Biliary Tract Neoplasms Clinical Trial
Official title:
Multicenter Study of EUS-guided Gallbladder Drainage vs Choledochoduodenostomy as First Line in Malignant Distal Obstruction in Palliative Patients (CARPEGIEM Trial): an Open-label, Randomized Controlled Clinical Trial
The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients.
Ecoendoscopy-guided choledochoduodenostomy (EUS-CDS) with a biliary lumen-apposing metal stent (LAMS) has been widely accepted as a second line treatment in cases of ERCP failure in malignant distal biliary obstruction (MDBO). Recent studies (DRAMBO and ELEMENT trial) compared EUS-CDS vs ERCP as a first line treatment in MDBO in palliative patients, showing similar clinical and techinal success and adverse events rate between both techniques, demonstrating that both procedures could be options for primary biliary drainage in unresectable MDBO. Furthermore a recent clinical trial (BAMPI trial) has proven that the addition of a coaxial double pigtail (DPS) offers benefits in terms of safey and clinical success. In the last years there has been an increasing interest for the EUS-guided gallblader drainage (EUS-GBD) in unresectable MDBO as an alternative for EUS-CDS, and recent studies and reviews have been reported with acceptable techinal and clinical success, but no clinical trial has been performed up to date. Our hypothesis is that EUS-GBD may offer benefits in terms of safety over EUS-CDS, maintaining similar clinical and techinal success rates. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Completed |
NCT03101566 -
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT05237193 -
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
|
||
Not yet recruiting |
NCT06037655 -
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
|
Phase 2 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Completed |
NCT00196105 -
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
|
N/A | |
Completed |
NCT02558959 -
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
|
Phase 2 | |
Completed |
NCT02829918 -
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
|
Phase 2 | |
Completed |
NCT02784353 -
Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy
|
N/A | |
Recruiting |
NCT05429203 -
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
|
N/A | |
Recruiting |
NCT02255669 -
Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction
|
N/A | |
Completed |
NCT01731821 -
Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
|
Phase 3 | |
Completed |
NCT00422409 -
Endoscopic Stenting of Gastrointestinal Cancer
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
Terminated |
NCT02615210 -
Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures
|
N/A | |
Completed |
NCT04595058 -
LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent
|
N/A | |
Recruiting |
NCT04856761 -
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
|
||
Recruiting |
NCT03427242 -
Apatinib for Advanced Biliary Carcinoma
|
Phase 2 | |
Recruiting |
NCT05615818 -
Personalized Medicine for Advanced Biliary Cancer Patients
|
Phase 3 |